March 27, 2026 - Key Regulatory Updates for Medical Device Professionals

Today's Regulatory Intel Summary

Today's regulatory landscape brings significant updates with the clearance of advanced imaging technologies, EU MDR compliance, FDA approvals for new treatments, and ongoing quality improvement efforts. Staying informed is crucial to maintaining compliance and innovation in your medical device operations.

Photon-counting CT Technology: Advancing Imaging Efficiency

GE Healthcare has advanced its imaging lineup with the clearance of a photon-counting CT (PCCT) system, featuring Photonova's PCCT technology. This 'universal scan' approach aims to enhance efficiency and reduce complexity across various CT exam types by providing higher spatial resolution and lower radiation dose compared to traditional CT systems. For QA/RA teams, this represents an opportunity to integrate more advanced imaging technologies that can improve patient outcomes while reducing costs and exposure risks.

Source: Medical Device Network

EU MDR Compliance for Sleep Insomnia Device

Neurovalens has successfully met the requirements of the EU Medical Device Regulation (MDR) with its Modius Sleep device, which is designed to treat prescribed insomnia. This compliance ensures that Neurovalens can continue to operate in the European market while maintaining high standards of safety and performance. QA/RA professionals should review their own devices for MDR alignment to ensure ongoing regulatory compliance.

Source: Medical Device Network

FDA Approves New Hunter Syndrome Drug

The FDA has approved Avlayah (tividenofusp alfa-eknm) for treating certain individuals with Hunter syndrome, a rare genetic disorder that affects the nervous system. This approval marks an important step in managing the neurologic manifestations of the disease through targeted therapy. QA/RA teams should monitor future clinical trials and regulatory updates to ensure their practices are aligned with these new therapeutic approaches.

Source: FDA Press Releases

FDA Launches National Priority Voucher Pilot Program

In a move to improve the quality and efficiency of regulatory processes, the FDA has initiated a Federal Register Notice for public comment on its Commissioner's National Priority Voucher pilot program. This initiative aims to streamline the approval process by offering vouchers that can be redeemed against expedited review fees. QA/RA teams should engage with this process to understand potential benefits and opportunities to speed up their product development timelines.

Source: FDA Press Releases

What QA/RA Teams Should Do This Week

QA/RA teams should proactively review and adapt their processes to incorporate the latest regulatory changes. Engage with ongoing initiatives like the FDA's National Priority Voucher program, ensure compliance with MDR for European operations, and stay informed about new treatments such as Avlayah. By doing so, your team can maintain a competitive edge in an ever-evolving regulatory landscape.